The restatement reveals material weaknesses in revenue recognition and expense accrual controls. Cash burn continues with only $45,622 cash and no revenue. Monitor for potential need for additional financing, further restatements, or delisting risk. The going concern qualification makes this a high-risk penny stock.
Price Chart
Executive Summary
Goldenwell Biotech filed Amendment No. 1 to its Form 10-Q for the quarter ended September 30, 2025, restating financials due to material errors identified by its auditor: improper revenue recognition on a service contract ($25,000 revenue reversed), misclassification of legal fees ($7,760 increase in expense), and incorrect OTCQB fee amortization ($2,670 correction). The restatement worsened the net loss from $(7,985) to $(27,895) for the quarter and increased the accumulated deficit to $(1,456,377). The going concern warning remains in place with minimal revenue and a working capital deficit.
Key Facts
- Net loss for Q3 2025 restated from $(7,985) to $(27,895) — a $19,910 increase in reported loss.
- Service revenue of $25,000 was improperly recognized and reversed to $0.
- Legal fees restated from $9,840 to $2,080, adding $7,760 to expenses due to historical period allocation.
- OTCQB fee expense corrected by $2,670 for misclassification of prepaid costs.
- Accumulated deficit grew to $(1,456,377) as of September 30, 2025.
- Total assets restated from $220,410 to $233,760; total liabilities restated upward by $62,500 to $377,733.
- Cash balance is only $45,622; working capital deficit is $(332,111).
- Company still has no revenue from product sales in Q3 2025 and a going concern warning.
Financial Impact
Net loss worsened by $19,910 for Q3 2025; accumulated deficit increased by $49,151 to $(1,456,377). Total liabilities rose $62,500 due to deferred revenue restatement.
Risk Factors
- Going concern risk remains with minimal cash and recurring losses.
- Material internal control weaknesses exposed by restatement could lead to future filing delays or SEC scrutiny.
- Restatement signals unreliable financial reporting, eroding investor confidence.
- $5 million in additional capital needed for manufacturing build-out with no committed financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-Q/A Filing (Primary) | 0001477932-26-004067 |
| Document: gdwl_ex312.htm | 0001477932-26-004067 |
| Document: gdwl_ex311.htm | 0001477932-26-004067 |
| Document: gdwl_ex321.htm | 0001477932-26-004067 |
| Document: gdwl_ex322.htm | 0001477932-26-004067 |
| Document: 0001477932-26-004067-index-headers.html | 0001477932-26-004067 |
| Document: 0001477932-26-004067-index.html | 0001477932-26-004067 |
| Document: 0001477932-26-004067.txt | 0001477932-26-004067 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | SC 13D | $0.6897 $0.6000 | ▼ −13.01% | ▼ −11.04% | $0.6500 (−5.76%) |
Oct 9, 2026 18d ago | 3 | $0.6897 $0.6000 | ▼ −13.01% | ▼ −11.04% | $0.6500 (−5.76%) |
Oct 9, 2026 18d ago | 8-K | $0.6897 $0.6000 | ▲ +13.01% | ▲ +11.04% | $0.6500 (+5.76%) |
Sep 29, 2026 27d ago | 8-K | $0.6897 $0.6897 | · 0.00% | ▲ +1.95% | $0.6500 (+5.76%) |
Jun 29, 2026 17w ago | 10-Q/A | $0.5200 $0.5200 | · 0.00% | ▲ +1.39% | $0.6500 (−25.00%) |
Jun 26, 2026 17w ago | 10-Q/A | $0.5200 $0.5200 | · 0.00% | ▲ +1.39% | $0.6500 (−25.00%) |
Jun 26, 2026 17w ago | 10-Q/A | $0.5200 $0.5200 | · 0.00% | ▲ +1.39% | $0.6500 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers